Human Cancer Antigen 242 CLIA Kit

Description

​​​​​​​

Background

​​​​​​​​​​​​​​The Human Cancer Antigen 242 CLIA Kit is designed, developed, and produced for the quantitative measurement of human CA 242 level in serum samples. The CA 242 assay is a two-site sandwich assay to determination the level of CA 242。 Assay calibrators, controls, or patient serum samples are added directly to a reaction vessel together with magnetic particles antibody. The magnetic particles capture the CA 242 in the form of “magnetic particles–CA 242 antibody–CA 242– acridinium ester CA 242 antibody”. Materials bound to the solid beads are held in a magnetic field while unbound materials are washed away. Then trigger solutions are added to the reaction vessel, and light emission is measured with the ECL100 or ECL 25 analyzer. The relative light units (RLU) are proportional to the concentration of a CA 242 in the sample. The amount of analyte in the sample is determined from a stored, multi-point calibration curve and reported in serum CA 242 concentration.

Selected Literature

​​​​​​​​​​​​​​1.Chan, S. H., Lindholm, L., Wong, L., &Oon, C. J. (1985). Tumour markers in hepatocellular carcinoma in Singaporean Chinese.Tumour Marker Antigen, Holmgren, J.(ed.), 106.
2.Gui, J. C., Yan, W. L., & Liu, X. D. (2014). CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a metaanalysis. Clinical and experimental medicine, 14(2), 225-233.
​​​​​​​3.Haglund, C., Lundin, J., Kuusela, P., & Roberts, P. J. (1994). CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. British journal of cancer, 70(3), 487

For in-vitro diagnostic use.